360 NEWS360 NEWS
Home / Business

Vanguards of Healthcare: Senseonics Extends CGM Life to a Year

“We have the best-in-class accuracy, especially at the low end for predicting hypoglycemia, which is really important because of that light generation,” says Senseonics CEO Tim Goodnow, explaining the company’s implantable Eversense continuous glucose monitor (CGM) to Bloomberg Intelligence. Goodnow...

Published
Original News Source Bloomberg — Business
Content & Media Rights Aditya Somani / Bloomberg — Business
Editorial Publisher 360 NEWS (Independent Media)
“We have the best-in-class accuracy, especially at the low end for predicting hypoglycemia, which is really important because of that light generation,” says Senseonics CEO Tim Goodnow, explaining the company’s implantable Eversense continuous glucose monitor (CGM) to Bloomberg Intelligence. Goodnow is referring to Eversense’s micro-fluorometer technology, which generates light to measure glucose levels. “And importantly, the accuracy has to be maintained on day 360.” In this Vanguards of Health
360°

360° PERSPECTIVE

Verified viewpoints, counter-arguments & evidence

Perspective details for this viewpoint are currently being verified by our editorial desk.

Related Stories

Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].